Egetis Therapeutics
4,57 SEK +2,58 %Vær den første som følger denne virksomhed
Egetis Therapeutics is a drug development company, focused on projects in late clinical development in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs. Examples of the company's drug candidates are Emcitate, which is developed for patients with MCT8 deficiency, and Aladote, which is developed to reduce acute liver damage.
Omsætning
22,6 mio.
EBIT %
-876,55 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
EGTX
Daglig lav / høj pris
4,48 / 4,62
SEK
Markedsværdi
1,14 mia. SEK
Aktieomsætning
446,26 t SEK
Volumen
98 t
Finanskalender
Delårsrapport
08.11.2023
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Peder Walberg | 13,5 % | 13,5 % |
| Peter Lindell och bolag | 10,3 % | 10,3 % |
Premium
Not activated
This content is for our Premium customers only.
Viser Alle indholdstyper
